BBR Partners LLC Lowers Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA)

BBR Partners LLC reduced its position in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) by 46.2% in the fourth quarter, Holdings Channel reports. The firm owned 70,000 shares of the company’s stock after selling 60,000 shares during the period. BBR Partners LLC’s holdings in Ikena Oncology were worth $115,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of Ikena Oncology by 5.6% in the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company’s stock worth $469,000 after purchasing an additional 14,319 shares during the last quarter. FMR LLC grew its stake in Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after buying an additional 18,607 shares in the last quarter. BML Capital Management LLC increased its holdings in shares of Ikena Oncology by 395.8% in the 4th quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock worth $5,881,000 after buying an additional 2,862,578 shares during the last quarter. NEA Management Company LLC raised its position in shares of Ikena Oncology by 5.3% during the 3rd quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock valued at $1,038,000 after buying an additional 30,013 shares in the last quarter. Finally, Peapod Lane Capital LLC bought a new stake in shares of Ikena Oncology during the 4th quarter worth $833,000. Institutional investors own 75.00% of the company’s stock.

Ikena Oncology Stock Performance

IKNA stock opened at $1.44 on Friday. The company has a market capitalization of $69.49 million, a PE ratio of -1.17 and a beta of 0.49. Ikena Oncology, Inc. has a one year low of $1.22 and a one year high of $1.94. The company’s 50 day moving average price is $1.49 and its two-hundred day moving average price is $1.62.

Ikena Oncology (NASDAQ:IKNA) last issued its earnings results on Tuesday, March 11th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. On average, research analysts predict that Ikena Oncology, Inc. will post -0.91 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Ikena Oncology in a research note on Monday, November 11th. Wedbush reiterated a “neutral” rating and issued a $2.00 price objective on shares of Ikena Oncology in a report on Monday, December 23rd.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.